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Summary  Four  thousand  new  cases  of  soft  tissue  sarcomas  are  diagnosed  each  year  in  France,
23% of  which  are  localized  in  the  abdomen  and  pelvis;  the  treatment  of  non-metastatic  tumor
is based  on  wide  surgical  resection,  the  quality  of  which  determines  the  long-term  outcome.
To ensure  appropriate  care,  the  European  Society  of  Medical  Oncology  (ESMO)  recommends
that any  patient  with  an  unexplained  soft  tissue  mass  (of  any  size  for  deep  lesions  or  of  >5  cm
for superﬁcial  lesions)  be  referred  to  a  specialized  center  with  capacities  for  multidisciplinary
team decision;  appropriate  imaging  should  be  performed  prior  to  treatment  and  a  percutaneous
image-guided  needle  biopsy  should  be  routinely  performed.  In  France,  clinical  and  pathology
networks  (NetSarc  and  RRePS)  currently  offer  patients  a  structured  means  to  make  a  system-
atic diagnosis  of  soft  tissue  sarcoma  and  help  to  provide  access  to  appropriate  treatment  in  a
specialized  center.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
Introduction
Sarcomas  are  rare  malignant  tumors  of  mesenchymal  origin,  that  arise  in  connective  tis-
sue,  in  contrast  to  the  more  frequent  and  better-known  carcinomas  of  epithelial  origin
[1].  Sarcomas  have  widely  diverse  pathologies  with  more  than  70  histological  subtypes  and
an  ever-Increasing  number  of  molecular  subtypes.  They  may  develop  at  any  age  including
childhood,  can  occur  anywhere  anatomically  from  head  to  foot,  and  are  of  varying  aggres-
siveness,  even  within  the  same  histological  subtype  [2,3].  There  are  three  principal  kinds  of
sarcoma  corresponding  to  different  clinicopathological  entities  with  individually  speciﬁc
progression,  and  speciﬁcally  different  management  strategies:  bone  sarcomas,  visceral
∗ Corresponding author.
E-mail address: charles.HONORE@gustaveroussy.fr (C. Honoré).
http://dx.doi.org/10.1016/j.jviscsurg.2015.05.001
1878-7886/© 2015 Elsevier Masson SAS. All rights reserved.
2 C.  Honoré  et  al.
s
c
t
o
a
d
t
A
n
d
g
r
u
a
e
g
E
T
m
h
m
c
m
u
b
w
t
a
u
w
t
i
b
F
u
p
m
a
p
s
a
w
[
d
i
o
m
r
w
p
b
(
m
0
b
A
a
s
0
(
i
l
c
Figure 1. Incidence of soft-tissue sarcoma as a function of age in
France. Cases per 100,000 inhabitants per year; age groups (years).
Table  1  Distribution  of  the  principal  histologic  sub-
types  of  soft-tissue  sarcoma  in  France  (2002  WHO
Classiﬁcation).
tumors  of24  
arcomas  that  develop  in  a  speciﬁc  organ  (the  most  typi-
al  being  gastrointestinal  stromal  tumors  [GIST]),  and  soft
issue  sarcomas  (STS)  arising  in  connective  tissue  and  extra-
sseous  connective  tissue;  these  represent  about  1%  of  all
dult  cancers  [4—6].  No  formal  etiology  has  so  far  been
eﬁned,  but  several  contributing  factors  have  been  iden-
iﬁed  (genetic  mutations  of  the  NF1RB1,  WRN,  p53,  and
PC  genes,  which  are  responsible  respectively  for  type  I
euroﬁbromatosis,  congenital  retinoblastoma,  and  the  syn-
romes  of  Li-Fraumeni,  Gardner,  and  Werner)  or  extrinsic
enetic  damage  (ionizing  radiation,  exposure  to  vinyl  chlo-
ide,  dioxin,  chlorophenol,  and  certain  viruses)  [2—7]. This
pdate  aims  to  clarify  recommendations  for  the  diagnostic
nd  therapeutic  management  of  STS,  which  are  infrequently
ncountered  and  poorly  understood  by  most  visceral  sur-
eons.
pidemiology
he  exact  annual  incidence  of  STM  is  unknown.  Several  esti-
ates  based  on  retrospective  analyses  of  cancer  registries
ave  been  attempted  [8—17].  These  studies  all  suffer  from
ethodological  bias  because  the  registries  were  set  up  to
ollect  data  based  on  the  organ  of  origin,  an  appropriate
ethodology  for  the  natural  history  of  carcinoma  but
nsuitable  for  sarcomas  that  may  arise  in  any  part  of  the
ody.  This  is  particularly  the  case  for  visceral  sarcomas,
hich  tend  to  be  misclassiﬁed  as  digestive  cancers  based  on
he  organ  in  which  they  arise.  Adult  registries  are  often  sep-
rate  from  pediatric  registries.  This  results  in  a  systematic
nderestimation  of  the  incidence  of  STS  [8—17].  In  addition,
hen  a  pathologist  who  is  unfamiliar  with  these  histological
ypes  of  tumor  performs  the  pathologic  analysis,  the  risk  of
nitial  diagnostic  error  ranges  from  10  to  25%  [13—17].  The
est  estimates  of  incidence  available  today  come  from  a
rench  study;  the  authors,  fully  aware  of  diagnostic  pitfalls,
sed  a  less  biased  methodology  based  on  a  systematic
rospective  re-analysis  of  all  tumor  specimens  where  a  for-
al  diagnosis  or  suspicion  of  sarcoma  had  been  made,  over
 period  of  two  years  from  158  public  and  private  practice
athologists  in  the  Rhône-Alpes  region  of  France.  Tissue
pecimens  were  reviewed  by  two  expert  pathologists  with
dditional  systematic  molecular  analysis,  and  all  samples
ere  reclassiﬁed  according  to  the  2002  WHO  classiﬁcation
18].  After  review  of  1287  tissue  blocks,  sarcoma  was
eﬁnitely  diagnosed  in  748  patients  between  2005  and  2007
n  an  area  with  a  population  of  about  6  million  people.  The
verall  and  age-adjusted  incidence  of  sarcoma  was  esti-
ated  at  6.2  and  4.8  cases  per  100,000  population  per  year,
espectively.  The  incidence  of  STS  and  visceral  sarcoma
ere  respectively  3.6  and  2.0  cases  per  100,000  population
er  year  [18].  The  overall  male  to  female  ratio  was  1.1/1,
ut  there  was  a  female  preponderance  of  visceral  sarcomas
1.4/1)  and  a  male  preponderance  for  STS  (1.3/1).  The
edian  age  at  diagnosis  was  60  years,  with  a  range  between
 and  92  years.  Eight  percent  of  patients  developed  sarcoma
efore  the  age  of  18,  and  28%  after  the  age  of  70  years.
 graphical  representation  of  the  evolution  according  to
ge  of  the  incidence  of  STS  is  shown  in  Fig.  1.  The  median
ize  of  the  lesion  was  6  cm,  with  extremes  ranging  from
.3—40  cm.  Localization  of  STS  was  truncal  in  40%  of  cases
17%  thoracic,  9%  retroperitoneal,  8%  pelvic  and  6%  abdom-
nal),  while  60%  of  STS  were  peripheral  (49%  localized  on  a
imb  and  11%  on  the  head  and  neck).  Of  the  433  diagnosed
ases  of  STS,  25  (5.8%)  arose  in  irradiated  tissues  [18].
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Sarcomas
Liposarcoma  1092  25.2
Undifferentiated
sarcoma
947  21.8
Leiomyosarcoma  741  17.1
Myxoﬁbrosarcoma  252  5.8
Angiosarcoma  219  5.0
Rhabdomyosar-
coma
215  5.0
Synovial  sarcoma  183  4.2
MPNST  115  2.6
Other  577  13.3
Mesenchymalintermediate
malignancy
Solitary  ﬁbrous
tumor
119
Desmoid  tumor  363
MPNST: malignant peripheral neural sheath tumors.
xtrapolation  of  these  data  to  the  overall  French  population
ed  the  authors  to  estimate  that  about  4000  new  cases  of
TS  were  diagnosed  annually  in  France  [18].  An  estimation
f  the  distribution  of  histologic  sub-types  is  illustrated
n  Table  1,  based  on  the  ﬁndings  of  the  Network  for
athologic  Registry  of  Sarcomas  (RRePS),  which  has  under-
aken  the  systematic  histopathologic  review  of  all  newly
iagnosed  cases  of  sarcoma,  GIST,  and  desmoid  tumors
19,20].
lassiﬁcation of soft tissue sarcomas
orrect  classiﬁcation  of  STS  is  imperative  from  the  very
eginning  of  management.  It  informs  and  guides  the
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diagnostic  and  imaging  work-up,  and  helps  to  establish  the
prognosis  on  which  therapeutic  management  decisions  will
be  based.  STS  are,  by  their  nature,  very  heterogeneous
and  so  complex  that  any  classiﬁcation  system  has  proved
inadequate  for  the  individual  case.  The  classiﬁcation  of
STS  is  therefore  based  on  a  composite  that  considers,  in
addition  to  general  clinical  data  such  as  age  and  primary
tumor  location,  three  major  factors:
• a  complete  descriptive  histologic  analysis  according  to  the
latest  WHO  classiﬁcation  terminology,  including  molecular
sub-typing  if  necessary;
• an assessment  of  tumor  aggressiveness  based  on  histologi-
cal  grade  as  deﬁned  by  the  National  Federation  of  Centers
for  Combatting  Cancer  (FNCLCC);
• assessment  of  tumor  extension  based  on  the  TNM  status  as
deﬁned  by  the  American  Joint  Cancer  Committee  (AJCC)
and  the  International  Union  Against  Cancer  (UICC)  [20].
WHO histological classiﬁcation
The  WHO  has  recently  updated  the  standard  histological
classiﬁcation  system  for  STS  [2].  This  distinguishes  12  major
categories  of  benign  and  malignant  soft  tissue  tumors
(Table  2a)  that  are  secondarily  subdivided  into  113  his-
tological  subtypes  [2].  This  is  an  analogous  classiﬁcation,
not  based  on  the  local  origin  of  the  tumor  but  rather  on
attempted  identiﬁcation  of  the  cellular  line  of  differen-
tiation  (fat,  smooth  muscle,  striated  muscle,  cartilage.  .  .)
taken  by  the  tumor,  i.e.  based  on  the  aspect  of  normal
tissue  that  the  tumor  most  closely  resembles.  This  classiﬁ-
cation  is  deﬁned  by  histological  arguments  based  on  optical
microscopy  with  the  addition  of  immuno-histochemical  anal-
ysis.  For  those  sarcomas  where  no  line  of  differentiation
is  clearly  identiﬁable,  molecular  biology  allows  identiﬁca-
tion  of  speciﬁc  molecular  abnormalities  that  have  now  been
characterized  for  almost  half  of  sarcomas.  These  identiﬁca-
tion  markers  allow  objective  and  reproducible  classiﬁcation
(Table  2b)  [21,22].  Sarcomas  can  currently  be  classiﬁed  into
ﬁve  major  categories:
• sarcomas  with  molecular  translocations;
• sarcomas  with  activating  mutations;
• sarcomas  with  inhibitory  mutations;
• sarcomas  with  simple  ampliﬁcations;
• sarcomas  with  complex  genomic  abnormalities  [22].
Beyond  a  strictly  nosologic  classiﬁcation,  molecular  diag-
nosis  of  sarcoma  has  allowed  regrouping  of  microscopically
disparate  tumors  that  have  identical  genetic  abnormali-
ties,  and  differentiation  of  morphologically  identical  tumors
that  present  with  different  molecular  abnormalities.  They
Table  2a  Histologic  classiﬁcation  (WHO).
Adipose  tumors
Fibroblastic/myoﬁbroblastic  tumors
Fibrohistiocytic  tumors
Smooth  muscle  tumors
Peri-angiocytic  tumors  (perivascular)
Striated  muscle  tumors
Vascular  tumors
Cartilaginous  and  osseous  tumors
GIST  (Gastro  Intestinal  Stromal  Tumor)
Nerve  sheath  tumors
Tumors  with  uncertain  differentiation
Unclassiﬁed  and  undifferentiated  sarcomas225
Table  2b  Soft-tissue  sarcomas  with  deﬁned  genetic
translocations.
Ewing  sarcoma t(11;22);t(21;22)
Synovial  sarcoma  t(X;18)
Alveolar  rhabdomyosarcoma  t(2;13);t(1;13)
Myxoid  liposarcoma  t(12;16);t(12;22)
Myxoid  chondrosarcoma  t(9;22)
Clear-cell  sarcoma  t(12;22)
Fibromyxoid  sarcoma  t(7;16);t(11;16)
Desmoplastic  tumor  with  small
round  cells
t(11;22)
Infantile  ﬁbrosarcoma  t(12;15)
Alveolar  sarcoma  of  soft  tissue  t(X;17)
Inﬂammatory  myoﬁbroblastic
tumor
t(2;19);t(1;2)
Angiomatoid  histiocytoﬁbroma  t(12;16);t(12;22)
have  also  provided  major  hope  for  therapies  targeting  the
molecular  abnormalities  with  chemotherapeutic  agents  that
currently  exist  or  are  in  the  process  of  development,  simi-
lar  to  the  revolutionary  results  of  imatinib  therapy  for  GIST
[23].
The FNCLCC histologic grade
Histologic  classiﬁcation  alone  cannot  provide  sufﬁcient
information  to  predict  the  clinical  course  of  the  disease.
Several  grading  systems  for  tumor  aggressiveness  have
been  proposed  since  the  work  of  Broders  in  1939,  but  the
most  precise  and  reproducible  predictor  is  tumor  grade,  as
deﬁned  by  the  FNCLCC  and  described  by  Trojani  et  al.  in
1984  [4,24—28].  This  grade  is  based  on  an  assessment  of
the  initial  untreated  tumor  combining  features  of  tumor  dif-
ferentiation,  mitotic  index  and  extent  of  tumor  necrosis  to
calculate  an  overall  score  equivalent  to  tumor  grade,  as
shown  in  Tables  3a  and  3b. This  grade,  however,  is  often
much  less  informative  than  histologic  subtype  analysis  in
the  case  of  some  particularly  aggressive  histological  types
such  as  alveolar,  epithelioid,  clear  cell,  undifferentiated,
round-cell  and,  rhabdomyosarcoma  and  Ewing  sarcoma.
TNM staging according to the UICC and AJCC
Beyond  the  intrinsic  characteristics  of  the  tumor,  diagnostic
imaging  to  determine  the  spread  of  the  disease  can  help
to  complete  staging  thus  enhancing  therapeutic  decisions.
This  staging  is  done  using  the  TNM  classiﬁcation  proposed
by  the  UICC  and  AJCC,  which  considers  the  size  and  extent
of  the  primary  tumor  (T),  regional  lymph  node  involvement
(N),  the  presence  of  metastasis  (M),  and  tumor  grade  (G)
(Tables  4a  and  4b)  [29].
Management strategy
Rare  cancers  pose  a  particular  problem  precisely  because
of  their  relative  scarcity,  resulting  in  failure  to  diagnose,
error  in  diagnosis,  inadequate  treatment,  lack  of  treatment
guidelines,  limited  access  to  complex  treatments  that  are
available  in  only  a  few  centers,  and  limited  access  to  clinical
trials.  Organization  of  care  at  the  national  level  can  help
to  mitigate  these  problems.  In  France,  the  management  of
sarcoma  is  based  on  two  national  networks  for  pathologic
diagnosis  and  clinical  treatment,  which  work  co-operatively.
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Table  3a  FNCLCC  histologic  grade.
Scores  Description
Tumoral  differentiation
Score  1  Sarcoma  resembling  normal  tissue
Score  2  Sarcoma  with  clearly  deﬁned
histologic  diagnosis
Score  3  Embryonic  sarcoma,  synovial
sarcoma,  epithelioid  sarcoma,
clear-cell  sarcoma,  alveolar
sarcoma  of  soft  tissue,
undifferentiated  sarcoma  and
sarcoma  of  uncertain  histologic
type
Mitotic  index  (1  high-powered  ﬁeld  =  0.1734mm2)
Score  1  0—9  mitoses  per  ten  high-powered
ﬁelds
Score  2 10—19 mitoses  per  ten
high-powered  ﬁelds
Score  3  More  than  19  mitoses  per  ten
high-powered  ﬁelds
Tumoral  necrosis
Score  1  No  necrosis
Score  2  Less  than  50%  tumoral  necrosis
Score  3  More  than  50%  tumoral  necrosis
Table  3b  FNCLCC  histologic  grade.
Grade  1 Grade  2 Grade  3
Sum  of  scores:  2—3Sum of  scores:  4—5Sum of  scores:  6—8
Table  4a  TNM  staging  factors  according  to  the  2010
AJCC/UICC  guidelines.
T1  Tumor  ≤  5  cm
T1a  Superﬁcial
T1b  Deep
T2  Tumor  >  5  cm
T2a  Superﬁcial
T2b  Deep
N0  No  lymph  node  invasion
N1  Lymph  node  invasion
M0  No  distant  metastases
M1  Distant  metastases
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Table  4b TNM  stage  according  to  the  2010  AJCC/UICC  guidel
Stage  IA  T1a  N
T1b  N
Stage  IB  T2a  N
T2b  N
Stage  IIA  T1a  N
T1b  N
Stage  IIB  T2a  N
T2b  N
Stage  III  T2a,  T2b  N
T1-2  N
Stage  IV T1-2  NC.  Honoré  et  al.
athology network
n  France,  since  the  early  1980s,  a  group  of  pathologists
ave  preferentially  worked  on  the  study  of  connective  tissue
nd  soft  tissue  sarcomas  in  adults.  Thanks  to  their  persever-
nce,  major  advances  have  been  achieved,  both  technically
nd  organizationally.  Despite  these  advances,  the  diagno-
is  of  STS  remains  difﬁcult.  The  risk  of  initial  diagnostic
rror  is  10—25%  if  a  pathologist  who  is  unfamiliar  with  these
istological  types  carries  out  the  pathologic  analysis.  Some-
imes  there  are  major  discrepancies  resulting  in  mistaking
 benign  lesion  for  a  sarcoma  (10%  of  cases)  or  mistak-
ng  a sarcoma  for  a  benign  lesion  (4%  of  cases)  [13—17].
wareness  of  the  consequences  that  such  misdiagnoses
ight  cause  led  this  group  of  experts  to  set  up  a  Referral
etwork  for  Pathology  of  Soft  Tissue  and  Visceral  sarco-
as  (RrePS)  (http://rreps.sarcomabcb.org/home.htm);  this
tructure  was  approved  in  October  2009  by  the  INCa  within
he  framework  of  the  2009—2013  National  Cancer  Plan  (Mea-
ure  20,  Action  20.3)  with  the  aim  of  ‘‘supporting  quality
nitiatives  within  the  anatomic-cytopathologic  community’’
nd  particularly  ‘‘in  order  to  enable  systematic  double-
eading  of  all  rare  malignant  tumors  and  lymphomas  that  is
ssential  for  diagnostic  conﬁrmation’’  [30—32].  The  objec-
ive  of  this  network  is  to  guarantee  a  second  pathologic
eading  without  additional  cost  for  any  new  case  of  soft
issue  or  visceral  sarcoma.  Other  objectives  of  the  net-
ork  have  been  to  improve  the  molecular  diagnosis  of  these
umors,  to  strengthen  databases  and  the  collection  of  tissues
o  build  a  national  virtual  tumor  bank,  to  develop  transla-
ional  research  activities  both  nationally  and  internationally,
o  improve  the  continuing  education  of  pathologists  within
nd  outside  the  network,  and  to  improve  patient  information
irectly  and  by  forging  strong  links  to  patient  associations.  In
rder  to  perform  these  functions,  the  network  was  organized
s  a  tri-partite  National  Co-ordinating  Center  with  sites
ocated  in  Bordeaux,  Lyon  and  Villejuif.  Nineteen  adjunct
xpert  referral  centers  were  appended  to  this  National  Co-
rdinating  Center,  whose  distribution  is  shown  in  Fig.  2.
ince  the  establishment  of  RRePS,  pathologists  have  been
equested  to  systematically  send  slides  of  any  newly  diag-
osed  STS  or  visceral  sarcoma  to  one  of  these  centers  for
eview  by  an  expert  pathologist.  During  the  ﬁrst  two  years  of
ts  existence,  8251  tissue  specimens  from  7429  patients  have
een  reviewed  by  the  RRePS.  Diagnoses  were  established  for
589  sarcomas,  1007  GIST,  363  desmoid  tumors,  729  tumors
f  intermediate  malignancy,  189  non-mesenchymal  malig-
ancies,  and  522  benign  mesenchymal  lesions.  The  number
f  sarcomas  and  GIST  that  were  reviewed  corresponded  to
bout  80%  of  cases  expected  during  this  period  and  were
ines.
0  M0  G1
0  M0  G1
0  M0  G1
0  M0  G1
0  M0  G2,  G3
0  M0  G2,  G3
0  M0  G2
0  M0  G2
0  M0  G3
1  M0  G1-3
0-1  M1  G1-3
Soft  tissue  sarcoma  in  France  in  2014  227
l cenFigure 2. RRePS network (red: coordinating center; blue: referra
sent  in  for  review  by  1240  of  the  1795  active  pathologists  in
France  (69%).  Re-reading  of  the  slides  by  RRePS  resulted  in  a
change  in  diagnosis  in  25%  of  cases  referred  because  of  diag-
nostic  uncertainty  and  in  8.5%  of  cases  sent  in  for  systematic
pathologic  re-reading  [19].Clinical network
In  parallel  with  these  pathology  initiatives,  the  organization
of  the  supply  of  care  for  adult  patients  with  rare  cancers
was  laid  out  in  measure  23,  Action  23.1  of  the  2009—2013
National  Cancer  Action  Plan  to  ‘‘Certify  referral  centers
for  rare  cancers’’.  Eight  national  expert  referral  centers
have  been  certiﬁed  so  that  any  patient  with  a  rare  cancer
can  receive  treatment  in  the  establishment  of  their  choice,
be  assured  of  an  expert  opinion  both  for  diagnosis  and
throughout  the  various  stages  of  their  disease,  and  be  eligi-
ble  for  inclusion  in  clinical  trials  to  facilitate  access  to  inno-
vative  therapies.  All  of  these  issues  are  improved  by  analysis
of  the  database  accumulated  and  collated  by  each  of
these  centers,  through  ongoing  monitoring  of  these  uncom-
mon  diseases.  This  has  resulted  in  the  birth  of  NetSarc,
a  Clinical  Reference  Network  for  Sarcoma-GIST-Desmoid
Tumors  (http://netsarc.sarcomabcb.org/home.htm),  which
pursues  ﬁve  objectives:  the  deﬁnition  of  recommendations
for  clinical  management;  organization  of  referral  resources
for  patient  management;  coordination  of  research;  partici-
pation  in  epidemiological  surveillance;  and  organization  of
a  structured  care  pathway  for  patients  and  for  physician
training  and  continuing  education.ter).
This  organization  is  centered  on  a  tripartite  national
reference  center  of  expertise  located  in  Paris,  Lyon  and  Bor-
deaux,  with  links  to  a  national  network  of  expert  centers,
operating  in  coordination  with  RRePS  (Fig.  3).  Although  the
European  Society  of  Medical  Oncology  (ESMO)  has  devel-
oped  speciﬁc  recommendations  that  have  been  adopted
as  standard  by  the  French  networks,  a  recent  prospec-
tive  study  evaluating  adherence  to  these  recommendations
in  the  Aquitaine  and  Midi-Pyrénées  regions  showed  that
20%  of  patients  had  undergone  operation  for  deep  sarcoma
without  pre-operative  imaging  and  48%  had  no  established
histological  diagnosis  at  the  time  of  surgery  [33,34].  These
aberrations  may  seem  trivial,  but  the  planning  and  execu-
tion  of  surgery  for  sarcoma  surgery  are  complex  and  highly
dependent  on  the  speciﬁc  histological  tumor  type  and  its
anatomical  relationships  to  surrounding  tissues  in  order  to
deﬁne  the  extent  of  resection  required  and  the  possible
need  for  adjunctive  reconstruction  or  space-ﬁlling  proce-
dures  [35,36].  These  considerations  should  be  addressed  at
the  outset  of  management,  even  before  diagnostic  sampling.
A  technically  inadequate  biopsy,  particularly  via  a  surgical
approach,  can  have  dramatic  consequences  with  the  risk
of  tumor  dissemination  into  planes  that  are  opened  up  to
spread,  making  subsequent  curative  surgery  more  difﬁcult
or  even  impossible.  For  retroperitoneal  STS,  an  interna-
tional  consensus  conference  consisting  of  the  world’s  leading
experts  has  now  clearly  deﬁned  the  techniques  for  plan-
ning  and  performing  an  adequate  surgical  resection  [36].
Several  studies-have  clearly  shown  that  management  of  STS
from  the  outset  at  a  high  patient-volume  center  of  exper-
tise  led  to  improved  local  control  in  extremity  sarcomas  and
228  C.  Honoré  et  al.
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•igure 3. NetSarc clinical network (Sarcoma referral centers).
mproved  survival  in  thoracic  or  abdominal  truncal  sarco-
as,  and  also  that  the  shortcomings  of  an  inadequate  initial
urgical  could  never  be  retrieved  by  subsequent  treatments,
o  matter  how  aggressive  [37—44].  A  recent  study  showed
hat  a  patient  who  was  not  managed  under  the  aegis  of  Net-
arc  was  three  times  less  likely  to  have  his  case  discussed
n  a  multidisciplinary  conference,  four  times  less  likely  to
ave  adequate  pre-operative  imaging,  and  ﬁve  times  less
ikely  to  have  a  histologic  diagnosis  established  prior  to
eﬁnitive  surgery  [34].  If  established  diagnostic  and  thera-
eutic  recommendations  are  followed,  a  patient  undergoing
urgery  for  a  retroperitoneal  STS  in  France  in  2014  has  a
6-month  median  survival  and  a  54%  5-year  disease-free
urvival  [42].  Factors  predictive  for  local  recurrence  were
ale  sex,  the  invasion  of  an  adjacent  organ,  intra-operative
reach  of  the  tumor,  and  non-expertise  of  the  surgeon
42].
ecommendations for management
tarting  in  2005,  the  ESMO  has  published  recommendations
hat  have  been  regularly  updated  to  assure  optimal  manage-
ent  of  sarcomas  [33,45,46].  These  recommendations  can
e  summarized  in  three  points:
the  need  for  appropriate  initial  imaging  before  treat-
ment,  i.e.  CT  for  deep  thoraco-abdominal  STS,  or  MRI
for  parietal  thoraco-abdominal,  extremity,  head  or  neck
sarcomas;
•
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v
fthe  need  for  co-axial  percutaneous  core  needle  biopsy
under  radiological  control  prior  to  any  surgical  treatment
(en-bloc  resection  without  tumor  rupture  is  an  alterna-
tive  to  percutaneous  biopsy  for  adult  patients  with  small
superﬁcial  lesions  <  5  cm);
the  need  to  refer  any  patient  with  an  unexplained  soft-
tissue  mass  larger  than  5  cm  if  superﬁcial  or  of  any  size  if
deeply  located  to  a  center  of  expertise  capable  of  provid-
ing  a  multidisciplinary  approach.  In  France,  this  referral
should  be  a  center  belonging  to  the  RRePS  or  NetSarc
networks.
onclusions
pproximately  4000  new  cases  of  STS  are  diagnosed  each
ear  in  France.  The  development  of  the  certiﬁed  RRePS
nd  NetSarc  networks  offers  a  structured  approach  to  make
 quasi-formal  diagnosis  of  STS  and  to  facilitate  access
o  the  necessary  pathology,  imaging  and  clinical  tools  to
haracterize  the  tumor,  assess  its  scope,  and  arrange  for
ppropriate  medical  and  surgical  treatment  in  a  special-
zed  center.  These  resources  also  allow  dissemination  of
he  culture  of  the  multidisciplinary  approach  to  manage-
ent  of  STS  and  help  to  inform  the  medical  community
bout  the  dangers  of  premature  and  inappropriate  inter-
ention  decisions  that  are  so  often  the  source  of  treatment
ailure.
Soft  tissue  sarcoma  in  France  in  2014  
Key  points
• There  are  more  than  70  histological  subtypes  of
sarcomas  that  can  develop  at  any  age,  including
childhood;  these  may  occur  at  any  anatomical
location  from  head  to  toe.
• Four  thousand  new  cases  of  STS  are  diagnosed
each  year  in  France,  of  which  23%  are  located
in  the  abdominal  area  (abdominal  organs,  pelvis,
retroperitoneum  and  abdominal  wall).
• ESMO  published  recommendations  for  management
of  STS  in  2005,  which  can  be  summarized  in  three
points:
◦ referral  of  any  patient  with  an  unexplained  soft
tissue  mass  (>  5  cm  if  superﬁcial,  or  of  any
size  if  deep)  to  a  center  that  can  provide  a
multidisciplinary  approach  to  management,
◦ systematic  performance  of  appropriate  imaging
prior  to  treatment  (CT  of  deep  thoraco-abdominal
lesions  or  MRI  for  lesions  of  the  thoraco-abdominal
parietes,  extremities,  head  or  neck),
◦ performance  of  co-axial  percutaneous  core  needle
biopsy  under  radiological  control  prior  to  any
treatment.  En  bloc  surgical  resection  without
tumor  violation  is  an  alternative  to  percutaneous
biopsy  in  adults  if  the  lesion  is  superﬁcial  and
<5  cm).
• The  classiﬁcation  of  an  STS  must  consider  the
entirety  of  clinical  information,  such  as  patient
age,  tumor  size  and  location;  complete  descriptive
histological  analysis  according  to  the  2012  WHO
classiﬁcation,  may  be  supplemented  by  molecular
analysis  where  necessary;  tumor  aggressiveness
should  be  evaluated  by  FNCLCC  histological  grade;
tumor  extent  should  be  assessed  by  the  TNM  stage  of
the  UICC  and  AJCC.
[
[
site, in the surveillance, epidemiology and end results pro-
gram, 1978—2001: an analysis of 26,758 cases. Int J Cancer
2006;119:2922—30.• When  histological  analysis  is  entrusted  to  a  non-
expert  pathologist,  the  risk  of  initial  diagnostic  error
is  10—25%;  4%  of  sarcomas  will  be  mistaken  for
a  benign  lesion  and  10%  of  benign  lesions  will  be
mistaken  for  sarcoma.
• The Reference  Network  for  Pathology  of  Soft
Tissue-GIST-Desmoid-Visceral  Sarcomas  (RRePS)  is  a
grouping  of  expert  pathologists  certiﬁed  by  INCa
whose  goal  is  to  offer  a  second  reading  of  any  new
cases  of  STS  or  visceral  sarcoma  at  no  additional
cost.
• The  Clinical  Reference  Network  for  Sarcomas-GIST-
Desmoids  (NetSarc)  is  a  group  of  practitioners
certiﬁed  for  their  expertise  by  the  INCa  whose  aim
is  to  deﬁne  recommendations  for  management,
to  organize  a  referral  structure  for  patient
management,  to  coordinate  research  activities,
to  participate  in  epidemiological  monitoring,  and
to  set  up  a  structured  care  pathway  for  patients
and  to  implement  physician  training  and  continuing
education.
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